Integra LifeSciences (NASDAQ:IART) Updates Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.530-0.610 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $410.0 million-$425.0 million, compared to the consensus revenue estimate of $417.3 million. Integra LifeSciences also updated its FY 2026 guidance to 2.400-2.500 EPS.

Analyst Ratings Changes

Several research firms have recently issued reports on IART. BMO Capital Markets initiated coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target for the company. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Thursday, June 18th. UBS Group assumed coverage on Integra LifeSciences in a research note on Tuesday. They issued a “neutral” rating and a $19.00 target price for the company. Wells Fargo & Company boosted their price target on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $18.43.

Integra LifeSciences Trading Up 1.2%

Shares of IART stock opened at $19.76 on Wednesday. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -3.06, a PEG ratio of 1.35 and a beta of 1.22. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The stock has a 50-day moving average of $17.61 and a 200-day moving average of $13.41.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in IART. Global Retirement Partners LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $25,000. Osaic Holdings Inc. raised its holdings in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares during the period. Virtu Financial LLC bought a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $124,000. Finally, Amundi lifted its stake in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 11,004 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.